These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 20501461)

  • 1. Disease classification: a pitfall of the ERA/EDTA registry?
    Tsakiris DJ; Simpson K; Stel V; Wanner C; Jager KJ
    Nephrol Dial Transplant; 2010 Aug; 25(8):2799. PubMed ID: 20501461
    [No Abstract]   [Full Text] [Related]  

  • 2. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study.
    Tsakiris DJ; Stel VS; Finne P; Fraser E; Heaf J; de Meester J; Schmaldienst S; Dekker F; Verrina E; Jager KJ
    Nephrol Dial Transplant; 2010 Apr; 25(4):1200-6. PubMed ID: 20037169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Renal insufficiency with light chain paraproteinemia].
    Weinand HA; Haberland K; Pudill R; Wirsing CH
    Med Welt; 1978 Mar; 29(9):346-9. PubMed ID: 416319
    [No Abstract]   [Full Text] [Related]  

  • 4. [Myeloma and the kidney].
    Linnanvuo-Laitinen M; Huttunen K; Timonen T
    Duodecim; 1987; 103(1):42-6. PubMed ID: 3111820
    [No Abstract]   [Full Text] [Related]  

  • 5. Reversal of dialysis-dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantation.
    Firkin F; Hill PA; Dwyer K; Gock H
    Am J Kidney Dis; 2004 Sep; 44(3):551-5. PubMed ID: 15332228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival.
    Abbott KC; Agodoa LY
    Clin Nephrol; 2001 Sep; 56(3):207-10. PubMed ID: 11597035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some characteristics of renal injury in plasma cell dyscrasias.
    Drazen F; Lenert P; Tepavcević P; Ilić V; Curić S; Uzurov V; Pejin D; Zupunski A; Vodopivec S; Djisalov M
    Przegl Lek; 1985; 42(4):372-4. PubMed ID: 4048521
    [No Abstract]   [Full Text] [Related]  

  • 8. The 2006 ERA-EDTA Registry annual report: a précis.
    Stel VS; Kramer A; Zoccali C; Jager KJ
    J Nephrol; 2009; 22(1):1-12. PubMed ID: 19229813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe renal failure in multiple myeloma.
    Cosio FG; Pence TV; Shapiro FL; Kjellstrand CM
    Proc Clin Dial Transplant Forum; 1980; 10():177-80. PubMed ID: 6810342
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiple myeloma in end-stage renal disease.
    Penfield JG
    Semin Dial; 2006; 19(4):329-34. PubMed ID: 16893412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal failure in myeloma: relationship with isoelectric point of immunoglobulin light chains.
    Melcion C; Mougenot B; Baudouin B; Ronco P; Moulonguet-Doleris L; Vanhille P; Beaufils M; Morel-Maroger L; Verroust P; Richet G
    Clin Nephrol; 1984 Sep; 22(3):138-43. PubMed ID: 6435919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal histological lesions and clinical syndromes in multiple myeloma. Renal Immunopathology Group.
    Pasquali S; Zucchelli P; Casanova S; Cagnoli L; Confalonieri R; Pozzi C; Banfi G; Lupo A; Bertani T
    Clin Nephrol; 1987 May; 27(5):222-8. PubMed ID: 3109793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
    Kaposztas Z; Kahan BD; Katz SM; Van Buren CT; Cherem L
    Transplant Proc; 2009 Dec; 41(10):4407-10. PubMed ID: 20005409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal crystal storing histiocytosis in a patient with multiple myeloma.
    Farooq U; Bayerl MG; Abendroth CS; Verma N; Talamo G
    Ann Hematol; 2009 Aug; 88(8):807-9. PubMed ID: 19119476
    [No Abstract]   [Full Text] [Related]  

  • 15. Association of systemic light-chain deposition disease and amyloidosis: a report of three patients with renal involvement.
    Jacquot C; Saint-Andre JP; Touchard G; Nochy D; D'Auzac de Lamartinie C; Oriol R; Druet P; Bariety J
    Clin Nephrol; 1985 Aug; 24(2):93-8. PubMed ID: 3930115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal insufficiency in myelomatosis. Causes and treatment].
    Knudsen LM; Hansen MT; Hippe E; Løkkegaard H
    Ugeskr Laeger; 1993 Nov; 155(47):3823-7. PubMed ID: 8256382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006.
    Kramer A; Stel V; Zoccali C; Heaf J; Ansell D; Grönhagen-Riska C; Leivestad T; Simpson K; Pálsson R; Postorino M; Jager K;
    Nephrol Dial Transplant; 2009 Dec; 24(12):3557-66. PubMed ID: 19820003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal lesions in dysproteinemias.
    Verroust P; Morel-Maroger L; Preud'Homme JL
    Springer Semin Immunopathol; 1982; 5(3):333-56. PubMed ID: 6223393
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical problems in kidney disorders associated with myeloma and other paraproteinemias].
    Merta M; Spicka I; Rysavá R; Zabka J; Tesar V; Zima T; Honsová E; Stejskalová A; Vorsilková M; Walterová J
    Sb Lek; 1996; 97(4):469-77. PubMed ID: 9424712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].
    Arenas Gracia M; Abad Gosálvez A; Colomina Avilés J; Pascual Pérez R; Ferriz Moreno P
    An Med Interna; 1995 Apr; 12(4):187-8. PubMed ID: 7620064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.